JP2020103296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020103296A5 JP2020103296A5 JP2020022516A JP2020022516A JP2020103296A5 JP 2020103296 A5 JP2020103296 A5 JP 2020103296A5 JP 2020022516 A JP2020022516 A JP 2020022516A JP 2020022516 A JP2020022516 A JP 2020022516A JP 2020103296 A5 JP2020103296 A5 JP 2020103296A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- cell
- cancer
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022149655A JP2022191248A (ja) | 2014-03-11 | 2022-09-21 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951110P | 2014-03-11 | 2014-03-11 | |
| US61/951,110 | 2014-03-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554633A Division JP6935195B2 (ja) | 2014-03-11 | 2015-03-10 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022149655A Division JP2022191248A (ja) | 2014-03-11 | 2022-09-21 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020103296A JP2020103296A (ja) | 2020-07-09 |
| JP2020103296A5 true JP2020103296A5 (https=) | 2020-11-12 |
| JP7152035B2 JP7152035B2 (ja) | 2022-10-12 |
Family
ID=52829314
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554633A Expired - Fee Related JP6935195B2 (ja) | 2014-03-11 | 2015-03-10 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
| JP2020022516A Active JP7152035B2 (ja) | 2014-03-11 | 2020-02-13 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
| JP2022149655A Pending JP2022191248A (ja) | 2014-03-11 | 2022-09-21 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554633A Expired - Fee Related JP6935195B2 (ja) | 2014-03-11 | 2015-03-10 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022149655A Pending JP2022191248A (ja) | 2014-03-11 | 2022-09-21 | 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20170002046A1 (https=) |
| EP (3) | EP3825327A1 (https=) |
| JP (3) | JP6935195B2 (https=) |
| CA (1) | CA2940252C (https=) |
| ES (2) | ES2723774T3 (https=) |
| WO (1) | WO2015138435A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60280B1 (sr) | 2013-03-12 | 2020-06-30 | Molecular Templates Inc | Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija |
| WO2017019623A2 (en) | 2015-07-26 | 2017-02-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| CN111909278B (zh) | 2014-01-27 | 2024-04-09 | 分子模板公司 | Mhc i类表位递送多肽 |
| ES2723774T3 (es) * | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| MX2017010072A (es) | 2015-02-05 | 2017-11-09 | Molecular Templates Inc | Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas. |
| AU2016271124C1 (en) | 2015-05-30 | 2020-05-14 | Molecular Templates, Inc. | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| US9957325B2 (en) * | 2015-10-13 | 2018-05-01 | Formurex, Inc. | Synthetic antibody mimic peptides |
| WO2018106895A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| EP3573648B1 (en) * | 2017-01-25 | 2023-11-22 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108130374B (zh) * | 2018-03-22 | 2020-09-15 | 青岛泱深生物医药有限公司 | 肾癌的诊断产品以及治疗药物组合物 |
| AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
| AR119677A1 (es) | 2019-01-23 | 2022-01-05 | Millennium Pharm Inc | Dominios de unión anti-cd38 |
| CN113454108B (zh) | 2019-01-23 | 2025-02-14 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| CN114423793A (zh) | 2019-09-18 | 2022-04-29 | 分子模板公司 | 包含志贺菌毒素a亚基支架的pd-l1结合分子 |
| WO2021102445A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| WO2022197945A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| KR102592304B1 (ko) * | 2021-07-22 | 2023-10-23 | 주식회사 에이조스바이오 | 신규 세포 투과성 펩타이드 및 이의 용도 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech, Inc., South San Francisco, Calif. | Her2 extrazellulare domäne |
| US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| US5909011A (en) | 1996-08-01 | 1999-06-01 | International Business Machines Corporation | Method and apparatus for modifying circuit having ball grid array interconnections |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1998011229A2 (en) * | 1996-09-10 | 1998-03-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| WO2001001748A2 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Peptide compounds that bind her2 |
| US7267973B2 (en) | 2000-03-22 | 2007-09-11 | Sibtech, Inc. | Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor |
| US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| WO2003055439A2 (en) | 2001-07-18 | 2003-07-10 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
| WO2003066854A1 (fr) * | 2002-02-04 | 2003-08-14 | Yoshida, Hideo | Agent anticancereux utilisant des variantes de verotoxines |
| US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| US7449480B2 (en) | 2002-05-14 | 2008-11-11 | Baylor College Of Medicine | Small molecule inhibitors of HER2 expression |
| US7019017B2 (en) | 2002-05-14 | 2006-03-28 | Baylor College Of Medicine | Small molecule inhibitors of HER2 expression |
| AU2003294023B2 (en) | 2003-01-03 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus HER2/neu, nucleotides encoding same, and uses thereof |
| US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
| JP2007517763A (ja) | 2003-08-01 | 2007-07-05 | エイアンドジー ファーマスーティカル インコーポレイテッド | Ｈｅｒ２アンタゴニストを用いた治療への感受性を回復させる組成物および方法 |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| FI20055417A0 (fi) | 2005-07-20 | 2005-07-20 | Glykos Finland Oy | Syöpäpesifiset glykaanit ja niiden käyttö |
| ES2493465T3 (es) | 2005-09-26 | 2014-09-11 | Molecular Templates, Inc. | Biblioteca a partir de toxinas mutantes y procesos de utilización de la misma |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| BRPI0720647A2 (pt) * | 2006-12-29 | 2014-01-14 | Osprey Pharmaceuticals Usa Inc | Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos |
| ES2798758T3 (es) | 2007-06-06 | 2020-12-14 | Sarepta Therapeutics Inc | Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US20120258104A1 (en) * | 2009-07-22 | 2012-10-11 | Cenix Bioscience Gmbh | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes |
| KR20130108069A (ko) | 2010-04-15 | 2013-10-02 | 알퍼 바이오테크, 엘엘씨 | Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도 |
| US9321847B2 (en) * | 2010-09-20 | 2016-04-26 | Ramot At Tel Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| RS60280B1 (sr) * | 2013-03-12 | 2020-06-30 | Molecular Templates Inc | Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija |
| CN111909278B (zh) * | 2014-01-27 | 2024-04-09 | 分子模板公司 | Mhc i类表位递送多肽 |
| ES2723774T3 (es) | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
-
2015
- 2015-03-10 ES ES15716202T patent/ES2723774T3/es active Active
- 2015-03-10 WO PCT/US2015/019684 patent/WO2015138435A1/en not_active Ceased
- 2015-03-10 CA CA2940252A patent/CA2940252C/en active Active
- 2015-03-10 EP EP20206135.4A patent/EP3825327A1/en not_active Withdrawn
- 2015-03-10 JP JP2016554633A patent/JP6935195B2/ja not_active Expired - Fee Related
- 2015-03-10 EP EP18212794.4A patent/EP3502134B1/en active Active
- 2015-03-10 EP EP15716202.5A patent/EP3116905B1/en active Active
- 2015-03-10 US US15/125,142 patent/US20170002046A1/en not_active Abandoned
- 2015-03-10 ES ES18212794T patent/ES2864124T3/es active Active
-
2020
- 2020-02-13 JP JP2020022516A patent/JP7152035B2/ja active Active
-
2022
- 2022-05-02 US US17/734,881 patent/US20220267384A1/en not_active Abandoned
- 2022-09-21 JP JP2022149655A patent/JP2022191248A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020103296A5 (https=) | ||
| JP6896021B2 (ja) | 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素ａサブユニット領域とを含む細胞毒性タンパク質 | |
| JP2020513779A5 (https=) | ||
| ES2812303T3 (es) | Anticuerpo que se une a CD3 humano | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| JP2020079267A5 (https=) | ||
| CA2206343C (en) | Reagents and processes for targeting mutant epidermal growth factor receptors | |
| JP2016512519A5 (https=) | ||
| US9056911B2 (en) | Antibody against carcinoembryonic antigen and uses thereof | |
| EP3661968B1 (en) | Nanoparticle platform for antibody and vaccine delivery | |
| JP2019126343A (ja) | 生体外での効率的な定向増幅用のキメラ抗原受容体及びその適用 | |
| EP4309677A1 (en) | Pd-l1 and tlr7 double-targeting nanobody coupling drug and use thereof in anti-tumor | |
| US20260035706A1 (en) | Fusion polypeptides | |
| WO2023125842A1 (zh) | 一种新型upar单域抗体的开发 | |
| WO2023125975A1 (zh) | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 | |
| CN116763936A (zh) | 抗人pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用 | |
| CN116568709A (zh) | 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用 | |
| US20220291215A1 (en) | Methods of identifying t cell receptors | |
| WO2021190550A1 (zh) | 含有保护肽的嵌合抗原受体及其用途 | |
| WO2023088295A1 (zh) | 一种多特异性抗体及其药物用途 | |
| CA3224617A1 (en) | Anti-trop2 single-domain antibody and use thereof | |
| CN117860786B (zh) | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 | |
| WO2025045097A1 (zh) | 靶向hbv全长包膜蛋白的单域抗体及其用途 | |
| WO2023116781A1 (zh) | 一种新型pd1单域抗体的开发 | |
| CN114716558B (zh) | 一种双特异性抗体及其治疗癌症的应用 |